Therapeutic Asset Ratings

502 results matching 1 filter

129,767 assets · 8,707 sponsors · 3,128 indications

Methodology v0.2

Asset	Sponsor	Phase	Rating
Puxitatug Samrotecan Ovarian Cancer	AstraZeneca	P1/2	CC (40)
T-Dxd Ovarian Cancer	AstraZeneca	P1/2	CC (40)
T-Dxd Pancreatic Neoplasm	AstraZeneca	P1/2	CC (40)
T-Dxd Prostate Cancer	AstraZeneca	P1/2	CC (40)
Torvutatug Samrotecan Ovarian Cancer	AstraZeneca	P1/2	CC (40)
Zirconium Zr 89 Crefmirlimab Berdoxam Colorectal Cancer	AstraZeneca	P1/2	CC (40)
Defosbarasertib Small Cell Lung Carcinoma	AstraZeneca	P2	C (39)
Autologous, Engineered T Cells Targeting Tp53 R175H Colorectal Carcinoma	AstraZeneca	P1	C (39)
Autologous, Engineered T Cells Targeting Tp53 R175H Pancreatic Adenocarcinoma	AstraZeneca	P1	C (39)
azd0022 Colorectal Cancer	AstraZeneca	P1	C (39)
azd0022 Non-Small Cell Lung Carcinoma	AstraZeneca	P1	C (39)
azd0022 Pancreatic Ductal Adenocarcinoma	AstraZeneca	P1	C (39)
AZD0240 Colorectal Carcinoma	AstraZeneca	P1	C (39)
azd0240: autologous, engineered t cells targeting kras g12d Colorectal Carcinoma	AstraZeneca	P1	C (39)
azd9592 Colorectal Neoplasm	AstraZeneca	P1	C (39)
NT-112 Colorectal Carcinoma	AstraZeneca	P1	C (39)
Osimertinib Colorectal Neoplasm	AstraZeneca	P1	C (39)
Surovatamig Diffuse Large B-Cell Lymphoma	AstraZeneca	P1	C (39)
Surovatamig High Grade B-Cell Lymphoma	AstraZeneca	P1	C (39)
Ulintoclax Pegondrimer Non-Hodgkin Lymphoma	AstraZeneca	P1	C (39)
[111in]-fpi-2107 Gastric Cancer	AstraZeneca	P1	C (37)
[111in]-fpi-2107 Head And Neck Squamous Cell Carcinoma	AstraZeneca	P1	C (37)
[111in]-fpi-2107 Pancreatic Ductal Adenocarcinoma	AstraZeneca	P1	C (37)
[111in]-fpi-2107 Renal Cell Carcinoma	AstraZeneca	P1	C (37)
[225ac]-fpi-2068 Gastric Cancer	AstraZeneca	P1	C (37)

Showing 401 to 425 of 502 assets

PreviousPage 17 of 21Next